YASA
1.2.2018 01:03:10 CET | Business Wire | Press release
YASA , the world’s leading manufacturer of axial-flux electric motors and controllers, today announced raising £15 million in growth funding . Universal Partners joins Parkwalk Advisors and other existing investors in the round, bringing the total raised by the company to £35 million.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180131005889/en/
This £15 million investment follows YASA’s signing of long-term development and supply agreements with customers in the automotive sector. The company has recently opened a new 100,000-unit capacity production facility in Oxford, UK to meet the growing demand for its products. Eighty per cent of YASA’s production is destined for export to automotive manufacturers across the world, including China.
The new production facility will be officially opened today by the Secretary of State for Business, Energy and Industrial Strategy, the Rt Hon Greg Clark MP . A range of YASA-powered vehicles will be on display at the event, including cars from Nissan, Jaguar Land Rover and Williams Advanced Engineering.
The Business Secretary Greg Clark MP said, “YASA is a brilliant example of what can be achieved when government, academia and industry come together to turn the best ideas from the best minds into scale-up companies.”
YASA’s innovative axial-flux electric motor design offers best-in-class power and torque densities and is ideally suited to both hybrid and pure electric vehicle applications . With YASA’s technology, automotive manufacturers have greater design flexibility to improve vehicle performance whilst reducing vehicle weight.
YASA motors and controllers enable automotive manufacturers to meet increasingly stringent emissions targets whilst delivering exciting driving experiences . In addition to automotive, YASA motors are used in marine applications and in aerospace where high power density and torque density are critical.
Dr. Chris Harris, YASA’s CEO said, “Our customers are looking to adopt innovative new technologies such as YASA’s axial-flux electric motors and controllers in order to meet the needs of the rapidly expanding hybrid and pure electric automotive market. This additional £15 million in growth funding will enable YASA to further invest in the volume production capacity necessary to meet our customers’ requirements, and to address markets beyond automotive including aerospace and marine.”
Andrew Birrell of Universal Partners - who joins YASA’s board - said, “YASA has unique and highly differentiated axial-flux motor technology that offers clear advantages in terms of power and torque density compared to their competition in class. We are pleased to have the opportunity to invest and are very excited by the prospects for the Company.”
Alastair Kilgour, Chief Investment Officer at Parkwalk Advisors said, “YASA has made excellent commercial progress over the past two years and we are pleased to continue to support the Company in this latest financing round. With the rapid growth of electrification in automotive and other sectors such as aerospace and marine, we believe YASA has huge business potential.”
EDITOR’S NOTES
YASA http://www.yasa.com/
YASA is the world’s leading manufacturer of axial-flux electric motors and controllers for automotive, aerospace and marine applications. YASA’s proprietary electric motor and controller products offer the smallest, lightest form factor for a given power and torque requirement. The privately-held company is based in Oxford, the UK’s automotive manufacturing heartland. Investors include Parkwalk Advisors and Universal Partners .
View source version on businesswire.com: http://www.businesswire.com/news/home/20180131005889/en/
Contact:
For all media enquiries, contact:
Tamara Sword
TRM&C
tamara@trmandc.co.uk
+44
(0)7906 638351
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom